US 11,697,687 B2
Selective elimination of erosive cells
Kalle Soederstroem, Bagsvaerd (DK); and Elisabeth Douglas Galsgaard, Bagsvaerd (DK)
Assigned to NOVO NORDISK A/S, Bagsvaerd (DK)
Filed by NOVO NORDISK A/S, Bagsvaerd (DK)
Filed on Dec. 18, 2019, as Appl. No. 16/718,935.
Application 16/718,935 is a continuation of application No. 15/355,087, filed on Nov. 18, 2016, abandoned.
Application 15/355,087 is a continuation of application No. 14/124,876, granted, now 9,512,228, previously published as PCT/EP2012/061583, filed on Jun. 18, 2012.
Claims priority of provisional application 61/501,533, filed on Jun. 27, 2011.
Claims priority of application No. 11170402 (EP), filed on Jun. 17, 2011.
Prior Publication US 2020/0109206 A1, Apr. 9, 2020
Int. Cl. A61K 39/395 (2006.01); C07K 16/28 (2006.01)
CPC C07K 16/2851 (2013.01) [C07K 16/2803 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01)] 13 Claims
 
1. A method for treating a subject having osteoporosis and bone erosion, the method comprising administering an anti-NKG2A antibody, or an antigen binding fragment thereof to said subject, wherein said antibody blocks inhibitory signaling by CD94-NKG2A receptors and is a non-depleting antibody, and wherein said antibody has a heavy chain comprising the CDR1, CDR2 and CDR3 of SEQ ID NO: 2 and a light chain comprising the CDR1, CDR2 and CDR3 of SEQ ID NO: 3, or wherein said antibody has a heavy chain comprising the CDR1, CDR2 and CDR3 of SEQ ID NO: 4 and a light chain comprising the CDR1, CDR2 and CDR3 of SEQ ID NO: 5.